Method for preparing ophthalmic preparation containing thymosin beta-4
The present invention relates to a method for manufacturing an ophthalmic preparation comprising thymosin β4. According to the inventive method, the manufacture of an ophthalmic preparation comprising thymosin β4 is carried out in the presence of an inert gas, thus the contact of thymosin β4 with oxygen is blocked and the oxidation of thymosin β4 can be prevented and the pharmacological activity of thymosin β4 maintains for long-term period. Therefore, the ophthalmic preparation prepared by the inventive method can maintain the pharmacological activity of thymosin β4 in a stable state for a long time.
1. A method for manufacturing an ophthalmic product comprising thymosin β4 and a container, said method comprising:
(i) providing a composition comprising (a) a thymosin β4 and (b) an excipient, wherein the composition is prepared by mixing (a) the thymosin β4 and (b) the excipient in the presence of an inert gas;
(ii) filling the composition comprising the (a) thymosin β4 and the (b) excipient into the container; and
(iii) sealing the container in the presence of an inert gas to give a sealed container containing the composition comprising the (a) thymosin β4 and the (b) excipient,
wherein the (b) excipient comprises sodium chloride, potassium chloride, calcium chloride hydrate, magnesium chloride hexahydrate, sodium acetate hydrate, and sodium citrate hydrate,
wherein the pH of the composition containing the (a) thymosin β4 and the (b) excipient ranges from 6.8 to 7.2, and
wherein the ophthalmic product maintains at least about 92% purity under the condition of 25° C., 40% Relative Humidity (RH) for 12 months.
2. The method of claim 1 , wherein the inert gas of (i) and (iii) is nitrogen or argon.
3. The method of claim 1 , wherein the amount of thymosin β4 in the ophthalmic product comprising thymosin β4 ranges from 0.05% (w/v) to 0.5% (w/v).
4. The method of claim 1 , wherein the container is selected from the group consisting of a glass container, a polypropylene container, and a low density polyethylene container.
5. The method of claim 1 , wherein the pH of the composition comprising the (a) thymosin β4 and the (b) excipient is adjusted by using an acid selected from the group consisting of hydrochloric acid, acetic acid, and phosphoric acid.
6. The method of claim 1 , wherein the pH of the composition comprising the (a) thymosin β4 and the (b) excipient is adjusted by using a base selected from the group consisting of sodium hydroxide, potassium hydroxide, and sodium hydrogen carbonate.
7. The method of claim 1 , wherein the step (i) further comprises filtering the composition comprising the (a) thymosin β4 and the (b) excipient using a filter.
8. The method of claim 1 , further comprising a step of providing the sealed container of the step (iii) into a pouch in the presence of an inert gas.
9. The method of claim 1 , wherein the (b) excipient comprises based on 712 g of solvent, 4.89 g of sodium chloride, 573 mg of potassium chloride, 366.72 mg of calcium chloride hydrate, 229 mg of magnesium chloride hexahydrate, 2.98 g of sodium acetate hydrate, and 1.3 g of sodium citrate hydrate.
10. The method of claim 9 , wherein the (a) thymosin β4 solution is a aqueous solution of thymosin β4 acetate.
11. The method of claim 1 , wherein, in the step (i), the thymosin β4 is mixed with a solvent in the presence of an inert gas while supplying the inert gas at speed of 100 ml/min to 140 ml/min into the solvent thereby removing oxygen dissolved in the solvent.
12. An ophthalmic product prepared by the method of claim 1 .